Literature DB >> 9263992

Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure.

Y Wang1, J R Pratt, B Hartley, B Evans, L Zhang, S H Sacks.   

Abstract

Persistent fibrin deposition has been observed in kidneys undergoing chronic rejection, and has been suggested to contribute to the obliteration of the vasculature in these grafts. The mechanisms leading to it are not clear. Fibrinolysis, the process to remove fibrin in tissues, is initiated by tissue type plasminogen activator (tPA) and suppressed by type 1 plasminogen activator inhibitor (PAI-1). To investigate their roles in chronic rejection and fibrin deposition, we serially examined the expression of tPA and PAI-1 in an unmodified chronic rejection model, using a Fisher 344 to Lewis rat renal transplant, at 0, 2, 4, 6, 10, 12, 16 and 20 weeks post-transplantation (N = 4 rats/time point in each group). We also analyzed fibrin deposition and the development of chronic changes in the grafts. Our results show that tPA was up-regulated only in the acute phase of rejection (P < 0.05), whereas PAI-1 was induced and persistently expressed during the progressive phase of chronic rejection, together with persistent fibrin deposition in the grafts. Immunohistochemistry showed PAI-1 was mainly localized to the damaged/proliferative vascular intima. The results suggest that persistent induction of PAI-1 may be responsible for the continuance of fibrin deposition, which is associated with irreversible damage and chronic graft loss.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263992     DOI: 10.1038/ki.1997.343

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Regulation of TGF-beta1/MAPK-mediated PAI-1 gene expression by the actin cytoskeleton in human mesangial cells.

Authors:  Chen Yang; Keyur Patel; Pamela Harding; Andrey Sorokin; William F Glass
Journal:  Exp Cell Res       Date:  2007-01-31       Impact factor: 3.905

2.  Anti-thrombin therapy during warm ischemia and cold preservation prevents chronic kidney graft fibrosis in a DCD model.

Authors:  F Favreau; R Thuillier; J Cau; S Milin; E Manguy; G Mauco; X Zhu; L O Lerman; T Hauet
Journal:  Am J Transplant       Date:  2009-12-02       Impact factor: 8.086

3.  Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy.

Authors:  Julian R Pratt; Miriam E Jones; Jun Dong; Wuding Zhou; Paramit Chowdhury; Richard A G Smith; Steven H Sacks
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

4.  Genetic and metabolic determinants of increased plasma plasminogen activator inhibitor-1 activity in children with renal transplants.

Authors:  Luis Aldámiz-Echevarría; Pablo Sanjurjo; Alfredo Vallo; Mireia Aguirre; Gustavo Pérez-Nanclares; Pilar Gimeno; Miguel Rueda; José Ignacio Ruiz; Juan Rodríguez-Soriano
Journal:  Pediatr Nephrol       Date:  2003-05-22       Impact factor: 3.714

5.  Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

Authors:  Florin L Craciun; Amrendra K Ajay; Dana Hoffmann; Janani Saikumar; Steven L Fabian; Vanesa Bijol; Benjamin D Humphreys; Vishal S Vaidya
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-09

6.  Adhesion: a confounding bias in murine cervical heterotopic heart transplantation.

Authors:  Jinghui Yang; Qi Chen; Fang Liu; Zhiren Fu; Quanxing Wang
Journal:  Am J Transl Res       Date:  2015-09-15       Impact factor: 4.060

7.  Thrombin stimulates synthesis of macrophage colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor by human proximal tubular epithelial cells in culture.

Authors:  Yuko Shimaya; Michiko Shimada; Yoshiko Shutto; Takeshi Fujita; Reiichi Murakami; Norio Nakamura; Hideaki Yamabe; Ken Okumura
Journal:  Nephron Extra       Date:  2012-01-25

8.  Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response.

Authors:  Lixin Fang; Koji Ohashi; Hayato Ogawa; Naoya Otaka; Hiroshi Kawanishi; Tomonobu Takikawa; Yuta Ozaki; Kunihiko Takahara; Minako Tatsumi; Mikito Takefuji; Toyoaki Murohara; Noriyuki Ouchi
Journal:  Physiol Rep       Date:  2022-03

Review 9.  Coagulation and Fibrinolysis in Kidney Graft Rejection.

Authors:  Giovanni Stallone; Paola Pontrelli; Federica Rascio; Giuseppe Castellano; Loreto Gesualdo; Giuseppe Grandaliano
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.